plumbagin has been researched along with Obesity in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Liang, D; Liu, L; Zhang, L | 1 |
Joshi, SG; Juvekar, AR; Martis, EAF; Munshi, RP; Pai, SA | 1 |
Gaur, IS; Gursahani, MS; Juvekar, AR; Mestry, SN; Munshi, RP; Pai, SA; Panchal, FH | 1 |
3 other study(ies) available for plumbagin and Obesity
Article | Year |
---|---|
Plumbagin alleviates obesity-related asthma: Targeting inflammation, oxidative stress, and the AMPK pathway.
Topics: AMP-Activated Protein Kinases; Animals; Asthma; Cytokines; Humans; Inflammation; Male; Mice; Obesity; Oxidative Stress | 2023 |
Plumbagin exerts antiobesity effects through inhibition of pancreatic lipase and adipocyte differentiation.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Cell Differentiation; Humans; Kinetics; Lipase; Male; Mice; Molecular Docking Simulation; Naphthoquinones; Obesity; Plant Roots; Plumbaginaceae; Rats; Rats, Wistar; Triglycerides | 2018 |
Plumbagin reduces obesity and nonalcoholic fatty liver disease induced by fructose in rats through regulation of lipid metabolism, inflammation and oxidative stress.
Topics: Adjuvants, Immunologic; Animals; Antioxidants; Fructose; Inflammation; Lipid Metabolism; Male; Naphthoquinones; Non-alcoholic Fatty Liver Disease; Obesity; Oxidative Stress; Random Allocation; Rats; Rats, Wistar | 2019 |